Emerging Genomic and Immunological Correlates Defining Oligometastatic Trajectories in Intermediate/High-Grade Soft-Tissue Sarcomas

TL;DR

This paper explores how genomic and immune factors can help identify a specific type of soft-tissue sarcoma that spreads in a limited way, potentially guiding better treatment strategies.

Contribution

The paper introduces emerging genomic and immunological markers that define oligometastatic soft-tissue sarcomas and suggest their use in guiding treatment decisions.

Findings

Low genomic complexity and a B-cell-rich tumor environment are linked to better outcomes in oligometastatic sarcomas.

High ctDNA levels and immunosuppressive environments correlate with more aggressive metastatic behavior.

AI and machine learning can integrate multi-dimensional data to predict metastatic behavior in sarcomas.

Abstract

Soft-tissue sarcomas (STSs) comprise a rare, heterogeneous group of mesenchymal malignancies in which histologic grade remains the strongest determinant of outcome, metastatic risk, and therapeutic strategy. Intermediate/high-grade STSs exhibit a pronounced propensity for early distant relapse, yet growing evidence indicates that metastatic behaviour is not uniform. Within this spectrum, an oligometastatic phenotype, characterised by a limited number of metastases, often confined to the lung, has emerged as a clinically and biologically distinct state associated with more indolent metastatic kinetics and improved survival when treated with aggressive local interventions. However, the criteria that define true oligometastatic STSs remain unsettled, and prospective evidence is lacking. Emerging molecular and immunological correlates provide a potential framework for biological triage. Low genomic complexity (low-risk CINSARC), a B-cell/TLS-rich tumour microenvironment, high immune-cytotoxic signatures, and persistently low or undetectable circulating tumour DNA (ctDNA) are each linked to reduced metastatic competence and may underpin oligometastatic trajectories. Conversely, high chromosomal instability, immunosuppressive microenvironments, and elevated ctDNA levels align with covertly polymetastatic biology despite limited radiographic disease. In this context, artificial intelligence and machinelearning approaches applied to computational genomics, immune profiling, imaging, and liquid-biopsy data offer a powerful strategy to integrate these multi-dimensional features and refine predictions of metastatic behaviour in STS. Oligometastatic STS therefore represents a biologically definable subset amenable to multimodal management integrating local ablative therapies, systemic agents, and immune-based strategies. Prospective, biomarker-stratified trials are needed to validate selection frameworks and optimise treatment sequencing in this evolving therapeutic space.

Figures